Download Sample Personalized Cancer Vaccines Market and Clinical Innovation Outlook 2022

Oncological segment has gained a great momentum with the advent of modern technologies and the better equipped sequencing methodology. Over the past years, there has been gradual paradigm shift from traditional medicine and accelerated acceptance towards the precision medication. Physicians are opting for the personalization of the medicines according to the genomic makeup of the patient.

During the last decade, great efforts have been made to develop immunotherapeutic approaches for the treatment of malignant diseases as alternatives to traditional chemotherapy and radiotherapy. A quintessential goal of immunotherapy in cancer is treatment with vaccines that elicit potent anti-tumor immune responses without side effects. The upsurge of immunotherapeutics in oncology is remarkable and the trail towards getting personalized is in future trends. With the development of the pharmacogenomics and genome mapping resolutions towards human genome are making personalized vaccines to be more efficacious. The platform for the personalization of vaccines had been built by the human genome project.

For Report Sample Contact: neeraj@kuickresearch.com

Report Weblink:https://www.kuickresearch.com/report-personalized-cancer-vaccines-market-and-clinical-innovation-outlook-2022.php

Table of Contents

1. Personalized Vaccine: Trail Towards Cancer
1.1 Prologue to Personalized Cancer Immunotherapy
1.2 Advent of Personalized Cancer Vaccine

2. Perception of Personalized Vaccinomics
2.1 Genetic Heterogeneity by HLA System
2.2 Genesis of Tumor Neoantigens

3. Identification of Tumor Neoantigens
3.1 Conventional Methodologies
3.2 Next Genome Sequencing Approach

4. Development of Personalized Vaccines
4.1 Development Process of Personal Cancer Vaccine
4.2 Economic Aspects of Personalized Cancer Vaccine

5. Mechanism of Personalized Vaccines
5.1 Rationale of Personal Cancer Vaccine
5.2 Neoantigens and Immune Interactions

6. Application of Neoantigens in Therapeutics
6.1 Adoptive T Cell Therapy
6.2 Checkpoint Blockade

7. Categories of Personalized Cancer Vaccines
7.1 Personalized Peptide Vaccination (PPV)
7.2 DNA Cancer Vaccines
7.3 RNA Based Vaccines
7.4 Dendritic Cell Vaccines
7.5 Whole Tumor Cell Vaccines
7.6 Recombinant Virus Vaccines


8. Biomarkers for Personalized Vaccines
8.1 Pharmacogenomic Biomarkers
8.2 Prognostic and Predictive Biomarkers
8.3 Immune Checkpoint Biomarkers

9. Personalized Vaccines for Varied Cancers
9.1 Melanoma
9.2 Lung Cancer
9.3 Breast Cancer
9.4 Colorectal Cancer
9.5 Leukemia
9.6 Prostate cancer
9.7 Cervical Cancer
9.8 Gastric Cancer
9.9 Brain Tumor
9.10 Renal Cancer

10. Pharmacogenomics of Personalization
10.1 Pharmacogenomics towards Genomic Polymorphism
10.2 Somatic Mutations in Cancer Pharmacogenomics
10.3 Applications of Pharmacogenomics

11. Personalized Vaccines Market Overview
11.1 Market Trends Towards Therapeutic Personalization
11.2 Mergers and Acquisitions for Personalized Therapy

12. Global Personalized Vaccines Market Dynamics
12.1 Personalization Growth Drivers
12.1.1 Increasing Cancer Incidences
12.1.2 Cancer Heterogenetic Environment
12.1.3 High Level of Specificity
12.1.4 Government Initiatives
12.1.5 Reduced Genome Sequencing Cost and Time
12.1.6 Sustained Level of Innovation
12.2 Personalization Major Challenges

13. Global Personalized Cancer Vaccines Market Future Aspects

14. Competitive Landscape
14.1 Advaxis Inc.
14.2 Avax Technologies
14.3 BioNtech
14.4 Celldex
14.5 Genentech Inc.
14.6 Genocea
14.7 ISA Pharmaceuticals
14.8 Merck and Co.
14.9 Moderna
14.10 Neon Therapeutics

Figure 1-1: Categorization of the Cancer Immunotherapeutics Towards Cancer Vaccines
Figure 1-2: Illustration of Advantages Provided by the Targeting Neoantigens
Figure 2-1: Distinguishing Features of Driver and Passenger Gene Mutations
Figure 3-1: Identification of Tumor Antigens by Conventional Approach
Figure 3-2: Number of Mutation Derived Neoantigens in Human Cancer
Figure 3-3: Identification of Tumor Specific Neoantigens by Next Generation Sequencing
Figure 4-1: Illustration of Development of personalized Cancer Vaccines
Figure 4-2: Estimated Cost for Cancer Cell’s Genome Sequencing (US$)
Figure 4-3: Estimated Economic (US$) and Timeline (Weeks) Projections of Personalized Cancer Vaccine
Figure 5-1: Illustration of Development of Personalized Cancer Vaccines
Figure 5-2: Immune Stimulation by T-Cells with Personalized Cancer Vaccine
Figure 5-3: Immune Response Stimulation by B Cells with Personalized Cancer Vaccines
Figure 6-1: Route of Action of Adoptive T-Cell Mechanism in Individual
Figure 6-2: Clinical Aspects of Tumor Infiltrating T Cells in Cancer
Figure 6-3: Typical Mechanism of T Cell Activation via Signal Binding
Figure 6-4: Schematic Representation of Evolution of CARs Design
Figure 6-5: Mechanism of Cell Checkpoint Blockade in Cancer Vaccines
Figure 6-6: Mechanism of Cytotoxic T-Lymphocyte Associated Antigen-4 (CTLA-4)
Figure 6-7: Mechanism of PDL-1 Checkpoint Blockade in Tumor Cells
Figure 7-1: Differences between Conventional and Personalized Peptide Vaccine
Figure 7-2: The Representation of Template of a Polypeptide DNA Vaccine
Figure 7-3: Principle Structure of Synthetic m-RNA Developed with Specific Antigen
Figure 7-4: Representation of Ex-Vivo Preparation of Dendritic Cell based Vaccines
Figure 7-5: The Tumor Microenvironment Suppresses Efficacy by DC based Vaccines
Figure 7-6: Mechanism of Personalized Autologous Whole Tumor Cancer Vaccine
Figure 7-7: Representation of Replicative Virus Encoding a HSP Gene for Antitumor Activity
Figure 8-1: Illustration of Various Types of Biomarkers in Personalized Medicine
Figure 8-2: Roadmap of Development of Predictive Biomarkers
Figure 8-3: High Throughput Immune Assessment for Biomarker Discovery
Figure 9-1: Alterations in Mechanism of Cell Cycle Control of CDKN2A
Figure 9-2: Illustration of Targetable Oncogenic Drivers in Non-Small Lung Cancer
Figure 9-3: Personalized Strategies to Attain the Target of Interest in Acute Myeloid Leukemia
Figure 9-4: Prevalence of Cervical Cancer in Women in Developed and Developing Countries
Figure 9-5: Proportion of Genetic Abnormalities Present in Gastric Cancer
Figure 9-6: Classification of Gliomas into Four Grades Based as WHO Classification
Figure 9-7: Illustration of Loss of VHL Expression Leads to Renal Cell Carcinoma
Figure 10-1: Demonstration of Genomic Polymorphism in Pharmacogenomics
Figure 10-2: The Sources of Pharmacological and Pharmacogenetic Variability’s
Figure 10-3: Applications of Pharmacogenomics in Cancer Precision Medicines
Figure 11-1: Personalized Cancer Vaccine Market Opportunity Assessment (US$ Million), 2017-2022
Figure 11-2: Representation of the Commercial Oncological Trials by Segment
Figure 12-1: Representation of Growth Drivers in Personalized Cancer Vaccines
Figure 12-2: Illustrations of the Reduced Sequencing Cost of Human Genome
Figure 12-3: Major Challenges faced by the Personalized Cancer Vaccines

Kuick Research is a market research and analytics company that provides targeted information for critical decisions at business, product and service levels. We are quick, predictive and known by the recommendations we have made in the past. Our result-oriented research methodology offers understanding of multiple issues in a short period of time and gives us the capability to keep you full with loads of practical ideas. By translating research answers into strategic insight and direction, we not only rate the success potential of your products and/or services, but also help you identify the opportunities for growth in new demographies and find ways to beat competition.

Neeraj Chawla
neeraj@kuickresearch.com
KuicK Research
New Delhi-110001
India

This release was published on openPR.